Top
Tay Sachs - Healing Genes
719
post-template-default,single,single-post,postid-719,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Tay Sachs

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells (DUOC-01)

Augmentation of Umbilical Cord Blood Transplantation for Inherited Metabolic Diseases With Intrathecal Administration of Human Umbilical Cord Blood-Derived Oligodendrocyte-Like Cells


Phase 1

DESCRIPTION:

Doctors at Duke University Medical Center are recruiting participants with an inherited metabolic disorder for a trial of an augmented cord blood transplant directly through the spinal cord, with the goal of achieving remyelination of neurons and decreased gliosis, as well as production of the needed enzymes to correct the disorder. This cell therapy treatment will be evaluated through brain MRIs and other neurocognitive tests. The therapy, DUOC-01, will be administered through a spinal cord (intrathecal) injection between 26 to 28 days after a cord blood transplant. DUOC-01 is a portion of the cord blood cells that are grown into a type of cell that will produce the lysosomal enzymes relevant to these disorders:

  • Adrenoleukodystrophy (ALD)
  • Batten Disease Hunter Syndrome (MPS II)
  • Krabbe disease (Globoid Leukodystrophy)
  • Metachromatic Leukodystrophy (MLD)
  • Niemann Pick disease type A or B
  • Pelizaeus-Merzbacher disease (PMD)
  • Sandhoff disease
  • Tay Sachs disease
  • Alpha Mannosidosis Sanfilippo (MPS III)

The researchers hope that the treatment will cause engraftment, or permanent growth, of the transplanted cells and a constant replacement source of the enzymes needed for a reduction or resolution of the disease.


PATIENT MUST:

  • ≥ 1 week to <22 years of age
  • a life expectancy of ≥ 6 months
  • Have neurologic evidence of their disease (via MRI, EEG, or clinical assessment, etc.)
  • Not be pregnant or breastfeeding
  • Be HIV-negative
  • Able to have an MRI scan or lumbar puncture
  • Have an available, matched unrelated cord blood

THE STUDY INVOLVES:

  1. Prescreening to confirm eligibility of the patient to participate.
  2. A cord blood transplant.
  3. A single spinal injection of the DUOC-01 therapy 26 to 28 days after step (2) .
  4. The patient will be closely observed for adverse reactions for ~24 hours.
  5. 1 month after therapy, a neurotoxicity screening will be required.
  6. Standard follow-up evaluations including MRI, EEG, nerve conduction and other neurocognitive testing will be conducted for 1 to 5 years’ time.

LOCATIONS AND CONTACTS:

Duke University Medical Center in Durham, NC is recruiting participants for this trial. Map

Contact: Jennifer Baker, RN  |  [email protected]

 

SPONSOR INFORMATION:

Joanne Kurtzberg, MD & The Marcus Foundation

Or go online:

https://clinicaltrials.gov/ct2/show/NCT02254863

 

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader